Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Context Therapeutics Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/31/2023 |
4
| Kantoff Philip W. (Director) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 25,000 options to buy
@ $0.87, valued at
$21.8k
|
|
05/31/2023 |
4
| West Linda (Director) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 25,000 options to buy
@ $0.87, valued at
$21.8k
|
|
05/31/2023 |
4
| Stacey Jennifer Evans (Director) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 25,000 options to buy
@ $0.87, valued at
$21.8k
|
|
05/31/2023 |
4
| BERMAN RICHARD J (Director) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 50,000 options to buy
@ $0.87, valued at
$43.5k
|
|
05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/27/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
03/22/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/22/2023 |
8-K
| Quarterly results |
02/21/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Bought 5,823 shares
@ $0.8415, valued at
$4.9k
|
|
02/14/2023 |
4
| Levit Alex C. (Chief Legal Officer, Corp. Sec) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 151,505 options to buy
@ $0.8407, valued at
$127.4k
|
|
02/14/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 287,544 options to buy
@ $0.8407, valued at
$241.7k
|
|
02/14/2023 |
4
| Minai-Azary Jennifer Lynn (CFO) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Granted 158,001 options to buy
@ $0.8407, valued at
$132.8k
|
|
02/14/2023 |
SC 13G
| Context Therapeutics Inc. reports a 7.3% stake in Context Therapeutics Inc. |
02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/06/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/06/2023 |
8-K
| Quarterly results |
01/30/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Bought 7,027 shares
@ $0.6974, valued at
$4.9k
|
|
01/27/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
01/23/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Bought 6,839 shares
@ $0.7166, valued at
$4.9k
|
|
01/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/10/2023 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 5% stake in Context Therapeutics Inc. |
01/09/2023 |
SC 13G/A
| HIRSCHMAN ORIN reports a 0% stake in Context Therapeutics Inc. |
01/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/19/2022 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Bought 20,000 shares
@ $0.7398, valued at
$14.8k
|
|
12/12/2022 |
4
| Levit Alex C. (Chief Legal Officer, Corp. Sec) has filed a Form 4 on Context Therapeutics Inc.
Txns:
| Bought 6,000 shares
@ $0.8491, valued at
$5.1k
|
|
12/08/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
12/01/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
11/17/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|
|
|